Compare CVS Health Corp (CVS) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Raytheon Technologies Corp — how do they compare? CVS Health Corp trades at $104.86 (market cap $135.48B), while Raytheon Technologies Corp trades at $193.93 (market cap $260.44B). The key difference: Raytheon Technologies Corp is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| CVS | RTX | |
|---|---|---|
Market Cap | $135.48B | $260.44B |
Sector | Health | Industrials |
52-Week High | $106.18 | $212.16 |
52-Week Low | $58.75 | $148.68 |
Enterprise Value | $202.02B | $292.55B |
Dividend Yield | 2.51% | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
RTX trades at $193.39, down 1.3% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $1.78 exceeding expectations of $1.51. Revenue grew to $88.60 billion in 2025, and net income margin improved to 8.03%. Recent contract wins, including a $515 million U.S. Navy radar award announced June 3, 2026, underscore its defense sector strength.
Outlook remains positive given earnings momentum and defense budget tailwinds, but valuation at a P/E of 36.85 poses a risk if growth slows. Analyst consensus price target of $213.00 suggests 10% upside, with no sell ratings among 26 coverage firms. Key risks include execution on production targets and geopolitical shifts affecting defense spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
